A new approach to disease-modifying drug trials in Parkinson's disease
about
Linked clinical trials--the development of new clinical learning studies in Parkinson's disease using screening of multiple prospective new treatmentsModelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease.
P2860
A new approach to disease-modifying drug trials in Parkinson's disease
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
A new approach to disease-modifying drug trials in Parkinson's disease
@en
type
label
A new approach to disease-modifying drug trials in Parkinson's disease
@en
prefLabel
A new approach to disease-modifying drug trials in Parkinson's disease
@en
P2860
P356
P1476
A new approach to disease-modifying drug trials in Parkinson's disease
@en
P2093
Mark Stacy
P2860
P304
P356
10.1172/JCI69690
P407
P577
2013-06-01T00:00:00Z